Cedilla Therapeutics Appoints Justin Birtz as Vice President, People and Culture
Cedilla Therapeutics, a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the appointment of Justin Birtz as vice president, people and culture. Mr. Birtz brings to the role nearly two decades of talent and organizational development experience.
Mr. Birtz joins Cedilla from BitSight, where he was director, people operations. There, Mr. Birtz designed and developed the company’s first programs in leadership development, new leader onboarding and performance management with the goal of evolving company culture and inspiring new ways of thinking. In his role at Cedilla, Mr. Birtz will align Cedilla’s mission, values and talent strategy to connect, engage and develop remarkable professionals who share a passion for improving the lives of patients.
“Justin will be instrumental in building internal initiatives to assure that each individual within our deeply skilled network can impact the company and its success,” said Sandra Glucksmann, Ph.D., chief executive officer of Cedilla. “I’m delighted to welcome him to the team.”
Prior to BitSight, Mr. Birtz was director, HR business partnership and director, learning and organizational development at iRobot. Previously, Mr. Birtz spearheaded growth initiatives as an HR manager at Imprivata, Teladoc and Symbotic. He holds a master’s degree in human resource management from Framingham State University and a bachelor’s degree in management from Isenberg School of Management, University of Massachusetts at Amherst.
“Cedilla is composed of many talented scientists and leaders,” commented Mr. Birtz. “I am excited to lead the efforts to develop this team, capitalizing on a diverse workforce that shares a passion for helping patients.”
Added Dr. Glucksmann: “Our company recognizes the importance of meeting goals together. We celebrate the achievements that move us one step closer to building an industry-leading platform and deep pipeline of targets to treat diseases caused by protein dysfunction.”
